-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The China Pharmaceutical Industry Information Center has screened 29 drugs whose patents will expire in 2022 through the new drug development monitoring database (CPM).
Table 1: 2025 Market Scale Forecast for Expired Drugs by Therapeutic Area/Generic Name
Source: Cortellis, organized by China Pharmaceutical Industry Information Center
The following is a sample hospital drug market performance of the six potential therapeutic areas of digestive system drugs, nervous system drugs, endocrine and metabolic regulation drugs, mental disorder drugs, urinary system drugs, and anti-tumor drugs, and the key indications in these fields.
Market Performance of Sample Hospital Drugs in Potential Treatment Areas
Market Performance of Sample Hospital Drugs in Potential Treatment AreasPotential therapeutic area 1: Digestive system drugs
Potential therapeutic area 1: Digestive system drugsJudging from the sales data of the national sample hospital drug market, the sales amount of digestive system drug sample hospitals in 2021 will be 19.
Figure 1: Historical market performance of digestive system drugs in sample hospitals from 2012 to 2021
Source: Drug Comprehensive Database (PDB), China Pharmaceutical Industry Information Center
Potential therapeutic area 2: Nervous system drugs
Potential therapeutic area 2: Nervous system drugsJudging from the sales data of the national sample hospital drug market, the sales amount of the nervous system drug sample hospital in 2021 is 17.
Figure 2: Historical Market Performance of Nervous System Drugs in Sample Hospitals from 2012 to 2021
Source: Drug Comprehensive Database (PDB), China Pharmaceutical Industry Information Center
Potential therapeutic area 3: endocrine and metabolic regulation drugs
Potential therapeutic area 3: endocrine and metabolic regulation drugsJudging from the sales data of the national sample hospital drug market, the sales amount of endocrine and metabolic regulation drugs in the sample hospital in 2021 will be 15.
Figure 3: Historical market performance of endocrine and metabolic regulation drugs in sample hospitals from 2012 to 2021
Source: Drug Comprehensive Database (PDB), China Pharmaceutical Industry Information Center
Potential therapeutic area 4: Drugs for mental disorders
Potential therapeutic area 4: Drugs for mental disordersJudging from the sales data of the national sample hospital drug market, the sales amount of mental disorder drugs in the sample hospital in 2021 will be 5.
Figure 4: Historical market performance of mental disorder medication in sample hospitals from 2012 to 2021
Source: Drug Comprehensive Database (PDB), China Pharmaceutical Industry Information Center
Potential therapeutic area 5: Urinary system drugs
Potential therapeutic area 5: Urinary system drugsJudging from the sales data of the drug market in sample hospitals across the country, the sales amount of urology drugs in the sample hospitals in 2021 is 940 million yuan, and the peak sales amount in 2019 reached 1.
Figure 5: Historical Market Performance of Urinary System Drugs in Sample Hospitals from 2012 to 2021
Source: Drug Comprehensive Database (PDB), China Pharmaceutical Industry Information Center
Potential therapeutic area 6: Antineoplastic drugs
Potential therapeutic area 6: Antineoplastic drugsJudging from the sales data of the national sample hospital drug market, the sales amount of antitumor drugs in the sample hospitals in 2021 will be 40.
Figure 6: Historical market performance of antitumor drugs in sample hospitals from 2012 to 2021
Source: Drug Comprehensive Database (PDB), China Pharmaceutical Industry Information Center
Distribution of popular research targets for key indications
Distribution of popular research targets for key indicationsNote: The data in this section are all from the Intelligent Drug Big Data Analysis Platform (PharmaONE) database of China Pharmaceutical Industry Information Center
Key indication 1: biliary atresia, cholestasis
Key indication 1: biliary atresia, cholestasis
Figure 7: Global drugs for biliary atresia and cholestasis involve a total of 71 targets - TOP10 targets
Figure 8: 13 targets are involved in Chinese drugs for biliary atresia and cholestasis - TOP10 targets
Key indication 2: Epilepsy
Figure 9: A total of 170 targets are involved in global epilepsy drugs - TOP10 targets
Figure 10: Chinese epilepsy drugs involve a total of 38 targets - TOP10 targets
Key Indications 3: Obesity, Diabetes
Figure 11: A total of 754 targets are involved in global drugs for obesity and diabetes - TOP10 targets
Figure 12: Obesity, diabetes Chinese drugs involve a total of 141 targets - TOP10 targets
Key indication four: schizophrenia
Figure 13: Global drugs for schizophrenia involve a total of 230 targets - TOP10 targets
Figure 14: Chinese medicines for schizophrenia involve a total of 52 targets - TOP10 targets
Key indication five: urinary incontinence, overactive bladder
Figure 15: Global drugs for urinary incontinence and overactive bladder involve a total of 94 targets - TOP10 targets
Figure 16: Chinese drugs for urinary incontinence and overactive bladder involve a total of 15 targets - TOP10 targets
Key indication 6: liver cancer, colorectal tumor, non-small cell lung cancer, solid tumor, brain cancer
Figure 17: Pan-cancer solid tumor global drugs involve a total of 114 targets - TOP10 targets
Figure 18: Pan-cancer solid tumor Chinese drugs involve a total of 37 targets - TOP10 targets
